CLL | Tumor

Navigating Chronic Lymphocytic Leukemia Diagnosis and Staging

July 28th 2021, 9:00pm


Although CLL follows a different staging format than other cancer types, diagnosing the disease properly can open the doors for more effective treatment and management strategies.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021, 1:00pm


About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Study Analyzes Quality of Life Research on Patients With CLL and Their Caregivers

July 22nd 2021, 6:00pm


More research is needed on how a chronic lymphocytic leukemia diagnosis can affect patients and their caregivers.

Novel BTK Inhibitor Well Tolerated in Patients with CLL, Other B-Cell Malignancies

July 21st 2021, 6:00pm


TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.

Drug Duo Boosts Outcomes in Elderly Patients With CLL

July 18th 2021, 9:00pm


Fixed-duration Venclexta plus Gazyva produced longer remissions than chemoimmunotherapy in elderly patients with chronic lymphocytic leukemia and other comorbidities.

Imbruvica-Venclexta Combo Superior to Chlorambucil-Obinutuzumab for CLL

June 16th 2021, 9:00pm


The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.

Front-Line Imbruvica-Venclexta Combo May Induce Durable Responses in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

June 10th 2021, 1:00pm


Treatment with this combination was associated with encouraging clinical responses in this patient population.

Calquence and Imbruvica Elicit Similar Survival Results in Previously Treated Patients with Type of Leukemia

June 8th 2021, 4:00pm


Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.

Cirmtuzumab Plus Imbruvica Led to Increased Response Rates in MCL and CLL

June 7th 2021, 9:00pm


Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Keep Inspiring

April 28th 2021, 12:30pm


Don’t let your disease define you